From intensifying therapy in ctDNA-positive bladder cancer to scaling it back in ctDNA-negative colon cancer, new data from ...

Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...

Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...

Bladder cancer is often overlooked, but a recent high-profile diagnosis is helping raise awareness. Football legend and Colorado head coach Deion Sanders recently revealed he had been diagnosed at age ...

To our knowledge, SunRISe-4 shows, for the first time, a benefit of the addition of the localised TAR-200 gemcitabine intravesical system to systemic checkpoint inhibition as neoadjuvant treatment in ...

Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, ...

This is the first meta-analysis comparing the overall survival of patients with limited-stage small cell bladder cancer who underwent radical surgery with platinum-based perioperative chemotherapy vs ...

The trial, also referred to as KEYNOTE-905, met its primary end point of EFS, resulting in a 60% reduction in the risk of tumor recurrence, progression, or death of patients treated with neoadjuvant ...